can't read?
DKFZ-PSMA-617 - a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer.
DKFZ-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients.